EP1631311A4 - Humanized anti-ccr2 antibodies and methods of use - Google Patents
Humanized anti-ccr2 antibodies and methods of useInfo
- Publication number
- EP1631311A4 EP1631311A4 EP03819151A EP03819151A EP1631311A4 EP 1631311 A4 EP1631311 A4 EP 1631311A4 EP 03819151 A EP03819151 A EP 03819151A EP 03819151 A EP03819151 A EP 03819151A EP 1631311 A4 EP1631311 A4 EP 1631311A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- humanized anti
- ccr2 antibodies
- ccr2
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09169287A EP2135619A1 (en) | 2003-12-10 | 2003-12-10 | Humanized anti-CCR2 antibodies and methods of use therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/039599 WO2005060368A2 (en) | 2003-12-10 | 2003-12-10 | Humanized anti-ccr2 antibodies and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09169287A Division EP2135619A1 (en) | 2003-12-10 | 2003-12-10 | Humanized anti-CCR2 antibodies and methods of use therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1631311A2 EP1631311A2 (en) | 2006-03-08 |
EP1631311A4 true EP1631311A4 (en) | 2007-04-11 |
Family
ID=34709648
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03819151A Ceased EP1631311A4 (en) | 2003-12-10 | 2003-12-10 | Humanized anti-ccr2 antibodies and methods of use |
EP09169287A Withdrawn EP2135619A1 (en) | 2003-12-10 | 2003-12-10 | Humanized anti-CCR2 antibodies and methods of use therefor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09169287A Withdrawn EP2135619A1 (en) | 2003-12-10 | 2003-12-10 | Humanized anti-CCR2 antibodies and methods of use therefor |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP1631311A4 (en) |
JP (1) | JP2007521248A (en) |
AU (1) | AU2003300896A1 (en) |
CA (1) | CA2529694A1 (en) |
IL (1) | IL172533A (en) |
MX (1) | MXPA06000176A (en) |
WO (1) | WO2005060368A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006015341A1 (en) * | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Use of an antibody, which specifically binds to the chemokine receptor 2, for the production of a medicament for the treatment of therapy-refractory multiple sclerosis and/or therapy-refractory rheumatoid arthritis in the subject |
RU2547595C2 (en) | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Anti-ccr2 antibodies |
US9127052B2 (en) | 2010-06-29 | 2015-09-08 | Centre National De La Recherche Scientifique | LLT-1 antibodies with new functional properties |
WO2013192596A2 (en) * | 2012-06-22 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind ccr2 |
BR112016019929A2 (en) | 2014-02-28 | 2017-10-17 | Astellas Pharma Inc | bispecific antibody binding to human tlr2 and human tlr4 |
WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058679A1 (en) * | 1998-05-09 | 1999-11-18 | Glaxo Group Limited | Antibodies to cd23, derivatives thereof, and their therapeutic uses |
WO2001057226A1 (en) * | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
WO2001070266A2 (en) * | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
WO2002062383A2 (en) * | 2001-02-08 | 2002-08-15 | Smithkline Beecham P.L.C. | Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
US20020150576A1 (en) * | 1998-07-23 | 2002-10-17 | Larosa Gregory J. | Humanized anti-CCR2 antibodies and methods of use therefor |
WO2002102853A2 (en) * | 2001-06-14 | 2002-12-27 | Isis Innovation Limited | Cd4-specific antibody trx1 and uses therefor |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
DE3853515T3 (en) | 1987-05-21 | 2005-08-25 | Micromet Ag | MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES. |
JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | Antibodies with domain-denaturing constants |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006408A1 (en) | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (en) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | Novel DNA and expression plasmid containing it |
US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
TW212184B (en) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5182366A (en) | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
US5948647A (en) | 1990-10-29 | 1999-09-07 | Chiron Corporation | Nucleic acids encoding antigen-binding sites specific for cancer antigens |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
DE69229477T2 (en) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methods for the production of humanized antibodies |
WO1994005695A1 (en) | 1992-09-10 | 1994-03-17 | New York University | Polypeptides of g-coupled receptor proteins, and compositions and methods thereof |
US5468707A (en) | 1992-12-01 | 1995-11-21 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Coordination catalyst systems |
DE614989T1 (en) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Method for in vivo selection of ligand binding proteins. |
US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
EP0740701B1 (en) | 1994-01-13 | 2006-12-06 | The Regents of the University of California | Mammalian monocyte chemoattractant protein receptors |
US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
US5856571A (en) | 1995-06-07 | 1999-01-05 | Cellpro, Incorporated | Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
WO2001078653A2 (en) * | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Graft rejection inhibition with ccr2 inhibitors |
-
2003
- 2003-12-10 AU AU2003300896A patent/AU2003300896A1/en not_active Abandoned
- 2003-12-10 EP EP03819151A patent/EP1631311A4/en not_active Ceased
- 2003-12-10 WO PCT/US2003/039599 patent/WO2005060368A2/en active Application Filing
- 2003-12-10 JP JP2005512414A patent/JP2007521248A/en active Pending
- 2003-12-10 MX MXPA06000176A patent/MXPA06000176A/en unknown
- 2003-12-10 CA CA002529694A patent/CA2529694A1/en not_active Abandoned
- 2003-12-10 EP EP09169287A patent/EP2135619A1/en not_active Withdrawn
-
2005
- 2005-12-13 IL IL172533A patent/IL172533A/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058679A1 (en) * | 1998-05-09 | 1999-11-18 | Glaxo Group Limited | Antibodies to cd23, derivatives thereof, and their therapeutic uses |
US20020150576A1 (en) * | 1998-07-23 | 2002-10-17 | Larosa Gregory J. | Humanized anti-CCR2 antibodies and methods of use therefor |
WO2001057226A1 (en) * | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
WO2001070266A2 (en) * | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
WO2002062383A2 (en) * | 2001-02-08 | 2002-08-15 | Smithkline Beecham P.L.C. | Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
WO2002102853A2 (en) * | 2001-06-14 | 2002-12-27 | Isis Innovation Limited | Cd4-specific antibody trx1 and uses therefor |
Non-Patent Citations (5)
Title |
---|
ALBINI ADRIANA: "HIV-1 Tat protein mimicry of chemokines", PROC. NATL. ACAD. SCI., vol. 95, October 1998 (1998-10-01), USA, pages 13153 - 13158, XP002146039, DOI: 10.1073/pnas.95.22.13153 * |
COMBADIERE: "Monocyte Chemoattractant Protein-3 is a functional ligand for CC Chemokine Receptors 1 and 2B", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 50, 1998, USA, pages 29671 - 29675 * |
GODISKA: "Monocte chemotactic protein-4: tissue-specific expression and signaling trhough CC chemokine receptor-2", J. LEUKOC. BIOL., vol. 61, March 1997 (1997-03-01), pages 353 - 360 * |
GONG: "Monocyte chemotactic protein-2 (MCP-2) uses CCR+ and CCR2B as its functional receptors", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 18, 2 May 1997 (1997-05-02), usa, pages 11682 - 11695 * |
SARAFI M.: "Murine Monocyte chemoattractant proetein (MCP)-5 a novel CC chemokine that is a structural and functional homologue of human MCP-1", J. EXP. MED., vol. 185, no. 1, 6 January 1997 (1997-01-06), USA, pages 99 - 109, XP055035882, DOI: 10.1084/jem.185.1.99 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005060368A2 (en) | 2005-07-07 |
EP2135619A1 (en) | 2009-12-23 |
WO2005060368A3 (en) | 2005-12-22 |
IL172533A0 (en) | 2006-04-10 |
JP2007521248A (en) | 2007-08-02 |
MXPA06000176A (en) | 2006-06-27 |
AU2003300896A1 (en) | 2005-07-14 |
CA2529694A1 (en) | 2005-07-07 |
EP1631311A2 (en) | 2006-03-08 |
IL172533A (en) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219487A1 (en) | Cd20-specific antibodies and methods of employing same cd20 | |
IL179102A (en) | Humanized fcγriib specific antibodies and methods of use thereof | |
IL178593A (en) | Fcγriib-specific antibodies and methods of use thereof | |
HK1099935A1 (en) | Anti-cd3 antibodies and methods of use thereof -cd3 | |
IL172689A0 (en) | Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
ZA200305825B (en) | Modified antibodies and methods of use | |
AU2003265522A1 (en) | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
TWI350291B (en) | Crystal of anti-egfr antibodies | |
EP1833849A4 (en) | Fc gamma riib-specific antibodies and methods of use thereof | |
EP1841452B8 (en) | Single domain antibodies against tnfr1 and methods of use therefor | |
ZA200507067B (en) | Antibodies against human IL-21 receptor and uses therefor | |
IL186659A0 (en) | Il-31 monoclonal antibodies and methods of use | |
EP1482984A4 (en) | Surrogate antibodies and methods of preparation and use thereof | |
SI1587542T1 (en) | Use of anti-cd100 antibodies | |
ZA200506790B (en) | Arylvinylazacycloalkane compounds and method of preparation and use thereof | |
EP1689346A4 (en) | Epha2 agonistic monoclonal antibodies and methods of use thereof | |
AU2002340167A8 (en) | Anti-hla-dr antibodies and the methods of using thereof | |
AU2003277259A8 (en) | Immunoassay and method of use | |
EP1591062A4 (en) | Magnetoencephalography device and method of using the same | |
IL172533A0 (en) | Humanized anti-ccr2 antibodies and methods of use | |
EP1699485A4 (en) | Anti-hydroxylase antibodies and uses thereof | |
IL172510A0 (en) | Antibodies and uses thereof | |
EP1633749A4 (en) | Deazaflavin compounds and methods of use thereof | |
EP1589033A4 (en) | Antibody and use thereof | |
EP1633850A4 (en) | Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051214 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1082205 Country of ref document: HK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070312 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101ALI20070306BHEP Ipc: A61K 39/395 20060101AFI20051228BHEP |
|
17Q | First examination report despatched |
Effective date: 20070803 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20091102 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1082205 Country of ref document: HK |